Meeting
2022 ASCO Annual Meeting
Clinical characteristics and outcome of a large cohort of patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.
Authors
Audrey-Anne Lamoureux
CHU Sainte-Justine, Montréal, QC, Canada
Audrey-Anne Lamoureux , Michael J. Fisher , Lauriane Lemelle , Elke Pfaff , Stefan M. Pfister , Dominik Sturm , David T.W. Jones , Daniel Orbach , Scott Raskin , Alexander E. Drilon , Michal Zapotocky , Christina Coleman Abadi , Marc Barritault , Pierre Leblond , Uri Tabori , Jordan R. Hansford , Craig Erker , Francois Doz , Theodore Willis Laetsch , Sébastien Perreault
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Citation
J Clin Oncol 40, 2022 (suppl 16; abstr 2052)
DOI
10.1200/JCO.2022.40.16_suppl.2052
Abstract #
2052
Poster Bd #
390
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Long-term control and safety of larotrectinib in a cohort of adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion primary central nervous system (CNS) tumors.
First Author: Sébastien Perreault
Poster
2022 ASCO Annual Meeting
Efficacy and safety of larotrectinib in pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive cancer: An expanded dataset.
First Author: Leo Mascarenhas
Poster
2022 ASCO Annual Meeting
Long-term efficacy and safety of larotrectinib in a pooled analysis of patients with tropomyosin receptor kinase (TRK) fusion cancer.
First Author: Alexander E. Drilon
Poster
2017 ASCO Annual Meeting
Phase 1/2 study of the selective TRK inhibitor larotrectinib in pediatric patients with cancer.
First Author: Noah Federman